Pharmaceuticals

Non-injectable Insulin Market 2025–2029: Tracking 12.8% CAGR Toward $1.64 Billion in Revenue

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the non-injectable insulin market from 2025–2034 with trusted insights from The Business Research Company

How Will The Non-injectable Insulin Market Size Evolve Between Now And 2029?

The obeticholic acid market size has seen rapid expansion in recent years. This market is expected to increase from $0.9 billion in 2024 to $1.01 billion by 2025, achieving a compound annual growth rate (CAGR) of 12.3%. Several factors contributed to its growth in the past, including the rising prevalence of primary biliary cholangitis (PBC), the growing incidence of non-alcoholic steatohepatitis (NASH), the developing healthcare infrastructure in emerging markets, enhanced rates of liver disease diagnostics and screening, increased healthcare spending, and investments in liver disease research.

The obeticholic acid market is projected to experience substantial expansion, reaching $1.64 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 12.8%. This anticipated growth during the forecast period is driven by factors such as the increasing incidence of primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH), a heightened need for novel liver disease therapies, increased understanding of liver diseases and their available treatments, and the broader availability of healthcare in developing markets. Key trends expected over the forecast period encompass its increasing use for non-alcoholic steatohepatitis (NASH) treatment, strategic alliances and collaborations to advance its development, the incorporation of digital health tools for patient monitoring and adherence, a pivot towards addressing non-alcoholic fatty liver disease (NAFLD), and progress in liver disease biomarkers and diagnostic technologies.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22079&type=smp

Which Key Drivers Are Powering Growth In The Non-injectable Insulin Market?

The increasing occurrence of liver conditions is anticipated to fuel the expansion of the obeticholic acid market in the future. Liver diseases involve ailments that hinder the liver’s proper functioning. This upward trend in liver disease cases stems from excessive alcohol intake, which damages liver cells and compromises the organ’s functional capacity, potentially resulting in liver inflammation, cirrhosis, and ultimately, liver failure. Obeticholic acid offers assistance to individuals suffering from liver ailments by activating the farnesoid X receptor (FXR). This activation leads to a reduction in bile acid buildup, a decrease in liver inflammation, and a deceleration of fibrosis progression, consequently enhancing liver function. An illustrative example from December 2024 highlights this trend: the Office for Health Improvement and Disparities, a UK-based government department, indicated that premature deaths from alcoholic liver disease rose by 3.6% in 2023, totaling 5,984, an increase from 5,776 in 2022. Consequently, the expanding incidence of liver diseases is propelling the growth of the obeticholic acid market.

How Is The Global Non-injectable Insulin Market Structured By Key Segments?

The obeticholic acid market covered in this report is segmented –

1) By Product Type: Tablets, Capsules, Other Product Types

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Primary Biliary Cholangitis, Nonalcoholic Steatohepatitis, Other Applications

Subsegments:

1) By Tablets: Immediate-Release Tablets, Extended-Release Tablets

2) By Capsules: Soft Gelatin Capsules, Hard Gelatin Capsules

3) By Other Product Types: Oral Suspensions, Injectable Formulations

What Future-Focused Trends Are Anticipated In The Non-injectable Insulin Market?

Major companies in the obeticholic acid market are actively developing innovative products, including farnesoid X receptor (FXR) agonists, with the goal of advancing liver disease treatment and achieving better patient outcomes. A farnesoid X receptor (FXR) agonist functions as a compound that activates the FXR, which is a nuclear receptor crucial for managing bile acid metabolism, inflammation, and fibrosis in the liver. These farnesoid X receptor (FXR) agonists contribute to improved liver function and are utilized in the management of conditions such as primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). For example, in February 2024, Intercept Pharmaceuticals Inc., a US-based biopharmaceutical company, disclosed that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Ocaliva, aimed at treating individuals with primary biliary cholangitis (PBC). The FDA’s acceptance of the supplemental New Drug Application (sNDA) for obeticholic acid (Ocaliva) represents significant regulatory progress toward validating its clinical benefits in the treatment of PBC.

Which Companies Hold A Competitive Edge In The Non-injectable Insulin Market?

Major companies operating in the obeticholic acid market are Pfizer Inc., GlaxoSmithKline (GSK), Gilead Sciences Inc., Amgen Inc., Genfit, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, WuXi AppTec, Bayer AG, Sumitomo Dainippon Pharma Co. Ltd., Horizon Therapeutics, Dr. Reddy’s Laboratories, Lupin Limited, Hepalink Pharmaceutical Group5, Alembic Pharmaceuticals, Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals, Viva Life sciences, Omgene Life Sciences Pvt. Ltd., Zydus Cadila

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/obeticholic-acid-global-market-report

Which Region Is Expected To Lead The Non-injectable Insulin Market In The Next Few Years?

North America was the largest region in the Obeticholic Acid market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the obeticholic acid market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=22079&type=smp

Browse Through More Reports Similar to the Global Non-injectable Insulin Market 2025, By The Business Research Company

Food Acidulants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/food-acidulants-global-market-report

Feed Acidifiers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/feed-acidifiers-global-market-report

Glutamic Acid Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/glutamic-acid-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795